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A novel transgenic mouse strain 
expressing pKcβii demonstrates 
expansion of B1 and marginal zone 
B cell populations
Ali A. Azar1,4, Alison M. Michie 2, Anuradha Tarafdar2, Natasha Malik 2, Geetha K. Menon3, 
Kathleen J. Till1, Nikolina Vlatković1,5* & Joseph R. Slupsky 1,5*
Protein kinase Cβ (PKCβ) expressed in mammalian cells as two splice variants, PKCβI and PKCβII, 
functions in the B cell receptor (BCR) signaling pathway and contributes to B cell development. We 
investigated the relative role of PKCβII in B cells by generating transgenic mice where expression of 
the transgene is directed to these cells using the Eµ promoter (Eµ-PKCβIItg). Our findings demonstrate 
that homozygous Eµ-PKCβIItg mice displayed a shift from  IgD+IgMdim toward  IgDdimIgM+ B cell 
populations in spleen, peritoneum and peripheral blood. Closer examination of these tissues revealed 
respective expansion of marginal zone (MZ)-like B cells  (IgD+IgM+CD43negCD21+CD24+), increased 
populations of B-1 cells  (B220+IgDdimIgM+CD43+CD24+CD5+), and higher numbers of immature B cells 
 (IgDdimIgMdimCD21neg) at the expense of mature B cells  (IgD+IgM+CD21+). Therefore, the overexpression 
of PKCβII, which is a phenotypic feature of chronic lymphocytic leukaemia cells, can skew B cell 
development in mice, most likely as a result of a regulatory influence on BCR signaling.
B cell receptor (BCR) signaling plays an essential role at critical stages of B cell  development1,2. In the bone 
marrow spontaneous and environmental ligand-induced tonic signals from this receptor aid the transition of 
developing B cells from one stage of differentiation to the next until they emerge into peripheral circulation. In 
the periphery, mature B cells move between secondary lymphoid organs where specific antigen recognition by 
BCR results in their activation and differentiation to ultimately generate cells that yield specific antibody produc-
tion and immune memory. Key signaling molecules have been found to be intricately linked to the stage specific 
responses of BCR signaling. While this is particularly true for the early stages of B cell differentiation where this 
relationship is well defined, the roles of signaling molecules involved in B cell fate decisions in the periphery are 
less well characterized and  understood2.
One such signaling molecule is Protein kinase Cβ (PKCβ), which plays a central role in the appropriate regula-
tion of B cell development and activation, including BCR  signaling3. It has been demonstrated that knock-down 
of the PKCβ gene, prkcb, in mice results in immunodeficiency that is reminiscent of X-linked immunodeficiency, 
and corresponds to impaired humoral immune responses and B cell  function4. PKCβ plays an important role in 
B cell development and activation, including BCR  signaling3,4.
A key target of PKCβ during BCR engagement is Bruton’s tyrosine kinase (Btk). PKCβ phosphorylates Btk 
to provide feedback inhibition of BCR signaling by blocking its ability to activate phospholipase Cγ2 (PLCγ2) 
and stimulate  Ca2+ release from intracellular  stores5. Genetic studies have confirmed a functional relationship 
between PKCβ and Btk, showing that there is great similarity of B cell-related phenotypes resulting from targeted 
disruption of the genes coding for these  proteins4,6–8. The gene coding for PKCβ, PRKCB, when transcribed is 
alternatively spliced to yield PKCβI and PKCβII, which differ from each other within their C-terminal 50 amino 
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 acids9,10. However, it is not clear whether these isoforms have redundant or specific functions in B cell develop-
ment and activation.
Our previous studies of PKCβII in the malignant cells of B lymphoproliferative disorders have shown that 
overexpression of this PKC isoform is a phenotypic feature of chronic lymphocytic leukaemia (CLL)  cells11. In 
addition, the Tcl1-transgenic mouse model of CLL demonstrates that PKCβ plays a key role in the pathogenesis 
of CLL, because PKCβ deficient mice do not develop CLL-like  disease12. One possible explanation for this is the 
severe reduction in numbers of marginal zone B cells (MZ B cells) and B-1 B cells in PKCβ knock out  mice4, 
since these are the cells from which CLL is thought to  arise13,14. Interestingly, in virtually all mouse models of 
CLL, malignant cells develop from an expanded B-1 B cell  compartment15–19, and this is similar to human disease 
which is preceded by a condition known as monoclonal B  lymphocytosis20. Based on these combined findings, 
we wanted to investigate the effect of PKCβII overexpression in the B cell compartment. Considering the role of 
PKCβ in modulating BCR signaling and in B cell development, particularly the development of B-1 and MZ B 
cells, we hypothesized that transgenic expression of PKCβII within B cells of mice might lead to an expansion 
in populations of these B cell types.
Materials and methods
Generation of the Eµ-PKCβII tg mice. To generate Eµ-PKCβIItg mice, a pBSVE6BK plasmid (kindly 
provided by Dr. Raif Geha, Harvard Medical School) which exploits the VH promoter and the IgH-enhancer to 
specifically direct expression of target genes in B cells was used (pEµ  vector21). The full length PKCβII coding 
sequence (2021-bp) was tagged with human influenza HA at its 3′ end by PCR, using the forward 5′-GAG AAT 
CGA TCA AGATG-GCT GAC CCG GCT GCG GGG CC-3′, and the reverse 5′-GAG AGT CGA CTC AAA GAG CGT 
AAT CTG GAA CAT CGT ATG GGT AGC TCT TGA CTT CGG GTT TTAAA-3′ primers (Eurofins MWG Operon, 
London UK) prior to cloning into the ClaI (all restriction enzymes used in this study are from New England 
Biolabs, Hitchin UK) and SalI sites of the pEµ vector. An intra- ribosomal entry site (IRES) was sub-cloned 
into the BamHI and SalI sites of the multiple cloning site (MCS) of mCherry, and the IRES-mCherry cod-
ing sequence was then sub-cloned into pEµ-PKCβIIHA using Not-I and Apa-I placing it in a 5′→3′ unilateral 
orientation between the PKCβIIHA and β-poly-globin coding sequences in the Eµ vector (Fig. 1A). This con-
struct was tested in the mouse B lymphoma cell line  A2022 where 2 × 106 cells were nucleofected™ with 2 µg 
pEµ-PKCβIIHA-IRES-mCherry using the solution V transfection kit and programme U-013 according to the 
manufacturer’s protocol (Lonza, Tewkesbury, UK) and fluorescence associated with the expression of mCherry 
observed (Fig. 1B). The construct containing pEµ-PKCβIIHA-IRES-mCherry was then digested with Pvu-I and 
Spe-I, DNA fragment purified and injected into pronuclei of zygotes isolated from C57Bl/CBA F1 hybrid mice. 
Mice generated from this procedure were screened for the presence of the transgene by Southern blot analysis 
on genomic DNA isolated from the tail and digested with SphI. Blots were hybridized with the mCherry specific 
DNA probe labeled with 32P-dCTP (Amersham Megaprime DNA Labelling System), essentially as described 
 previously23. Founders were identified by higher expression, and/or evidence of a single integration site for the 
transgene (Fig. 1C), and those showing transgene integration in their genome were chosen for further breeding 
to generate the heterozygous and ultimately homozygous Eµ-PKCβIItg transgenic animals that were analysed 
in this study. To establish the first-generation of Eμ-PKCβII heterozygous mice, the founder mouse was back-
crossed with C57BL/6 wild type mice to generate F1 progeny. The heterozygous mice from this crossing were 
then selected and inter-crossed to generate F2 progeny. Some of these F2 mice were homozygous, and, at this 
point, we reconsidered the line established and these mice were used for phenotypical characterization as well 
as for breeding to expand the line. Eµ-PKCβIItg, littermate wt and non-littermate control mice were all main-
tained under identical conditions. Mice were generated and bred in-house within the Biological Services Units 
at the University of Liverpool and the University of Glasgow. Animal experiments were performed with appro-
priate approval and licenses from the UK Home Office. All experimental procedures involving animals were 
performed in accordance to guidelines approved by Animal Welfare and Ethical Review Bodies at the University 
Figure 1.  Generation of Eµ-PKCβII transgenic mice. (A) Schematic representation of the plasmid construct 
(pEµ-PKCβII-IRES-mCherry) used to generate transgenic mice. (B) A20 cell line transfected with pEµ-
PKCβII-IRES-mCherry plasmid using nucleofection. White arrow indicates fluorescent A20 cells that were 
succesfully transfected and express mCherry. Yellow arrow indicates those cells which did not take up the 
plasmid. (C) Southern blot analysis of genomic DNA isolated from tail cuttings of transgenic progeny to identify 
potential Eµ-PKCβIIItg founder mice. Copy number of the inserted gene was estimated by the accompanying 
standard curve of plasmid DNA. (D) Immunoblot analysis of protein extracted from splenic and liver tissue 
of homozygous Eµ-PKCβIItg mice. Western blots were performed using antibodies against HA (upper panel) 
or β-actin (lower panel). As positive control, protein lysates prepared from A20 cells that had been transiently 
transfected with pEµ-PKCβII-IRES-mCherry. (E) Upper and midde panel. Respective western blot analysis 
of PKCβII and β-actin expression in splenic tissue of wt (n = 3) and Eµ-PKCβIItg (n = 4) mice. Lower panel. 
Comparison of PKCβII expression in wt and Eµ-PKCβIItg mice. Expression of PKCβII was quantitated relative 
to β-actin. (F) Immunohistochemical staining of spleen sections from Eµ-PKCβIItg and wt mice with anti-HA 
(stained with Fast Red) and anti-PKCβII antibodies (brown with DAB). With respect to Eµ-PKCβIItg mice, the 
spleen sections are sequential where upper and lower images can be superimposed using the white arrow which 
points to the MZ and the yellow arrow which points to the follicle. The images in parts (C–E) have been cropped 
to efficiently show the relevant details, uncropped images can be viewed in the Supplementary information 
accompanying this manuscript. All elements of this figure have been published in the PhD thesis of AAA 43.
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of Liverpool and University of Glasgow and were carried out in accordance with standard animal housing condi-
tions under local and home office regulations.
Western blot analysis. Proteins were extracted from tissue samples as described  previously23. Briefly, snap 
frozen tissue samples were homogenised under liquid nitrogen using pestle and mortar. The homogenised tis-
sue was resuspended in buffer containing 20 mM HEPES, 25% glycerol, 0.42 M NaCl, 1.5 mM  MgCl2, 0.2 mM 
EDTA, 1 mM DTT, 1 mM PMSF and the following protease inhibitors: aprotinin (2 µg/ml), leupeptin (0.5 µg/
ml), pepstatin A (1 µg/ml) and soybean trypsin inhibitor (100 µg/ml), subjected to 3 freeze/thaw cycles and then, 
following centrifugation, the supernatant was collected and protein concentration determined using a modified 
Bradford (BioRad, Hemel Hampstead UK). Equal amounts of protein were separated by SDS-PAGE, transferred 
on to Immobilon™ membranes (Millipore, Fisher Scientific UK Ltd, Loughborough, UK), and Ponceau-S stain-
ing was used to verify equivalent protein loading. The membranes were probed with the following antibodies 
according to established  protocol11: PKCβII (C-18, Santa Cruz, Insight Biotechnology Ltd, Wembley UK) or 
HA [clone C29F4, (Cell Signaling Technologies, Hitchin, UK) or clone 16B12 (Covance, Cambridge Bioscience, 
Cambridge UK)] at a dilution of 1:1,000. Following incubation with secondary HRP-conjugated antibodies, 
protein bands were visualized using enhanced chemiluminescence (ECL) according to manufacturer’s protocol 
(GE Healthcare Life Sciences, Little Chalfont UK).
Histopathology and immunohistochemistry. Splenic tissue was fixed in 10% neutral buffered forma-
lin and then embedded in paraffin. To remove paraffin and rehydrate splenic sections a PT Link device (DAKO, 
Stockport UK) was used according to the manufacturer’s instructions. Immunohistochemical staining was 
performed using a DAKO Auto-stainer automated slide processing system and the EnVision™ FLEX/HRP kit 
(DAKO, K8012). The primary antibodies used were PKCβII (C-18) and HA (C29F4). Hematoxylin and eosin 
(H&E) staining of splenic sections was carried out according to standard protocols.
cell preparation. Peritoneal cells were removed by injecting 5–10 ml ice cold modified PBS (1% BSA + 0.1% 
Sodium Azide, pH 7.2) into the peritoneal cavity followed by withdrawal of the peritoneal exudates. Spleens 
were removed and mechanically disrupted to prepare single cell suspensions. Erythrocytes in peripheral blood, 
peritoneal and splenic samples were lysed by treating with 0.165 M ammonium chloride, prior to washing the 
cell suspensions.
Flow cytometry. Flow cytometry was employed to characterize mature B cell subsets in spleen, peritoneum 
and peripheral blood comparing Eµ-PKCβII tg mice with wt mice, as indicated. Cells (2–5 × 106) were suspended 
in 200 µl modified PBS, then antibody cocktails were added and the cell suspension was incubated on ice for 
30 min in the dark. Following this the cells were washed with 300 µl modified PBS, and then centrifuged at 
2,000 rpm at 4 °C for 2 min. The supernatant was decanted and the pellet was re-suspended in 300 µl modified 
PBS. Labeled cells were acquired using a LSR-Fortessa flow cytometer (BD Biosciences) and analyzed using 
FACSDIVA™ and FlowJo™ (BD Biosciences, UK) software packages. Fluorescence-conjugated antibodies were 
purchased from BioLegend (London, UK) unless otherwise stated: Living  Colors® DsRed mCherry (PT3647-
2, Clontech), CD45R/B220-PE (RA3-6B2), CD5-PE/Cy5 (53–7.3), IgD-APC (11-26c.2a), CD43-FITC (S11), 
IgM-APC/Cy7 (RMM-1), CD21/CD35-PE/Cy7 (7E9), CD24-PerCP/Cy5.5 (M1/69), FITC-Rat IgG2bκ Isotype 
Ctrl (RTK4530) and CD45R/B220-Alexa  Fluor® 488 (RA3-6B2). The percentage of B cell subsets, including FO 
 (IgD+IgMdim), MZ  (IgDdimIgM+CD43negCD21+CD24+) and B-1  (B220+IgDdimIgM+CD43+CD24+) B cell popula-
tions were largely similar between wt littermate and non-littermate animals (data not shown), therefore non-
littermate and littermate wt mice were considered a single group of wt mice.
Calcium flux. Calcium flux analysis in isolated cells was carried out as described  previously24. Briefly, splenic 
cells from Eµ-PKCβII tg hom/het mice were labelled with 1 μM Fura-2 AM (Invitrogen Ltd.) in buffer (145 mM 
NaCl, 5 mM KCl, 1 mM  MgSO4, 1 mM  CaCl2, 10 mM HEPES, 0·18% glucose and 0·2% BSA, adjusted to pH 7.4) 
at 37 °C for 30 min in the dark. Cells were washed, incubated with 10 μg/ml biotinylated anti-IgM for a further 
30 min at 4 °C, washed and re-suspended at 1 × 106/ml in buffer. Cells (1.5 × 106) transferred to the fluorimeter 
cuvette were allowed to warm to 37 °C for 3 min prior to data acquisition. After recording basal fluorescence, 
50 µl avidin was added to crosslink the BCR (final concentration 8.3 µg/ml) and recording continued for a fur-
ther 3 min. Fluorescence was measured at 340 and 380 nm using a Hitachi F-7000 Fluorescence Spectrophotom-
eter (Hitachi High Technologies America, Inc., Schaumburg, IL, USA).
Ig concentration analysis. Blood was extracted from mice and serum was prepared by pelleting the RBCs 
at 12,000g for 10 min. The serum was aliquoted and stored at – 20 °C until needed. Assays of IgM concentration 
in serum were performed using the LEGENDplex™ kit (BioLegend, UK) following the manufacturers’ instruc-
tions. IgM concentrations were calculated using the LEGENDplex™ data analysis software dongle.
Statistical analysis. All statistical analyses in this study were performed using GraphPad  Prism® 8 software.
Results
Characterization of Eµ-PKCβII transgenic mice. Based on the Southern blotting analysis, the number 
of pEµ-PKCβIIHA-IRES-mCherry transgene copies integrated in the single site of the founder mouse genome 
was estimated to be greater than one, but less than 10 copies (Fig. 1C). PKCβIIHA expression was then ana-
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lysed by Western blot analysis and detected in spleen but not in liver of 6 month-old mice homozygous for the 
PKCβIIHA transgene (hereafter Eµ-PKCβIItg mice) (Fig.  1D), suggesting that transgene expression is tissue 
specific. A comparison of total PKCβII expression in protein extracts derived from the splenic tissue showed 
that PKCβII was expressed at significantly higher levels in Eµ-PKCβIItg mice compared with wt counterparts 
(Fig. 1E). In addition, analysis of HA expression within the spleen revealed that expression was concentrated 
within the follicle area of the peri-arteriolar lymphoid sheaths (PALS) and MZ, both of which are B cell rich areas 
(Fig. 1F). Although total PKCβII expression in the spleen of transgenic and wt mice showed a similar staining 
pattern, the intensity of staining was always greater in the tissue from transgenic mice where it correlated with 
that of HA. We were not able to detect the expression of mCherry in Eµ-PKCβIItg mice (data not shown). This 
may be because expression of a secondary gene from an IRES sequence can be variable and not always efficient 
in transgenic mice and therefore might have been below detection  level25.
Eµ-PKCβIItg mice aged normally and did not show any signs of illness when aged up to 14 months. The 
WBC count of Eµ-PKCβIItg mice was in a normal range and did not differ from that in wt mice (Table 1). In 
addition, the spleen weight did not change significantly between Eµ-PKCβIItg mice and wt mice, and although 
there appeared a small but significant increased ratio of B cells to combined T/B lymphocytes in the spleen of 
EµPKCβIItg compared to wt mice, this ratio remained similar in the peripheral blood and peritoneum between 
these animals.
Splenic tissue from Eµ-PKCβIItg mice display an expansion of the MZ B cell population and 
a concomitant reduction of the FO B cell population. Although total B cell counts were similar 
between EµPKCβIItg and wt mice, differences were observed between discrete populations. We applied the 
gating strategy shown in Supplementary Figure 2 for the analysis of B cells within splenic tissue from wt and 
Eµ-PKCβIItg mice. Thus,  B220+ cells were first analysed for surface IgD and IgM expression. Eµ-PKCβIItg mice 
exhibited an increased percentage of  IgD+  IgM+ B cells and decreased percentage of  IgD+  IgMdim B cells com-
pared to wt control mice (Fig. 2A,B). Analysis of the  IgD+  IgMdim B cells identified them as mainly FO B cells 
because of their expression of CD21 and CD24, the phenotype of these cells seemed consistent between wt and 
Eµ-PKCβIItg mice (Supplementary Figure 2), despite lower numbers of these cells in the latter. The  IgD+  IgM+ 
B cells were further gated for CD43 expression, and cells negative for this antigen were further analyzed for 
CD21 and CD24 expression. The major population identified,  IgD+IgM+CD43negCD21+CD24+, are “MZ-like” 
in phenotype and resemble a described precursor MZ cell population known as marginal zone precursor B 
 cells26,27. This population of “MZ-like” B cells showed significantly greater representation in splenic tissue from 
Eµ-PKCβIItg compared to wt mice, suggesting a strong bias towards this phenotype in the former (Fig. 2C). 
The bias towards this MZ-like phenotype was further corroborated by H&E stains showing an extended MZ 
in Eµ-PKCβIItg compared with wt mice (Fig. 2D, upper panels), identified by anti-IgM staining (Fig. 2D, lower 
panels). Interestingly, this is the same area that seemed to stain strongly for PKCβII and HA in splenic tissue of 
transgenic mice (Fig. 1F). Of note,  IgD+  IgM+  CD24+  CD43neg cells negative for CD21 were present in splenic 
tissue from Eµ-PKCβIItg, but not from wt mice. This population may represent immature B cells but was not 
further analysed in this study. Functional analysis of splenic B cells from transgenic animals showed that BCR-
induced  Ca2+ flux was significantly suppressed in cells isolated from Eµ-PKCβIItg mice (Fig. 2E), an observation 
that is in line with the role of PKCβ in regulating the function of Btk and PLCγ2-induced calcium  release5. Thus, 
these data suggest that B cell-targeted over-expression of PKCβII functionally restricts antigen receptor signal-
ing resulting in an expansion of splenic MZ B cells in Eµ-PKCβIItg mice.
The peritoneum of Eµ-PKCβII transgenic mice contains an elevated B-1 cell population. Peri-
toneal  B220+ B cells exhibited a significant decrease in the percentage of  IgD+  IgMdim cells, coupled with signifi-
cant increase in the percentage of  IgDdim  IgM+ cells in Eµ-PKCβIItg mice when compared to wt mice (Fig. 3A,B, 
Supplementary Figure 3). Further analyses revealed that the populations of  IgD+  IgMdim cells defined by CD24 
and CD43 expression were largely similar between wt and Eµ-PKCβIItg mice (Supplementary Figure 3). How-
Table 1.  Comparison of spleen weight, WBC count and B/B + T lymphocyte ratio in Eµ-PKCβIItg and 
wt control mice. B/B + T lymphocyte ratio in spleen, peritoneum and peripheral blood were determined 
using a FACS-based protocol identifying B cells  (B220+CD5− live lymphocytes) and T cells  (B220−CD5+ live 
lymphocytes). Statistical analysis was performed using a Mann–Whitney U-test.
Wild type Std Eµ-PKCβIItg Std P value
Spleen weight (mg) 129.4n = 7 9.02
120.4
n = 9 5.9 0.63
WBC count (× 106 per ml) 3.02n = 7 0.78
3.74
n = 11 0.62 0.41
B cell/B + T cells
Spleen 0.60n = 10 0.046
0.73
n = 13 0.064 0.024
Peritoneum 0.85n = 6 0.014
0.87
n = 10 0.024 0.25
Peripheral blood 0.71n = 4 0.063
0.65
n = 10 0.052 0.44
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ever, similar analysis of  IgDdim  IgM+ cells showed that the proportion of  CD24+CD43+ cells in Eµ-PKCβIItg mice 
was significantly increased compared to wt mice (Fig. 3C). These cells carry a B-1 B cell phenotype  (B220+  IgM+ 
 IgDdim/−  CD43+  CD24hi) and are likely to be B-1a cells because the majority of them are also positive for CD5 
Figure 2.  Effect of B cell-targeted expression of PKCβII on B cell populations in splenic tissue from 
Eµ-PKCβIItg and wt mice. Single cell suspensions prepared from spleens isolated from Eµ-PKCβIItg and wt 
mice were stained with a cocktail of antibodies containing B220, IgM, IgD, CD43, CD21 and CD24 markers, 
and then analysed by flow cytometry. Quantitative comparisons were then made of the percentage  B220+ cells 
within the following gates (A)  IgD+  IgMdim, (B)  IgD+  IgM+, and (C)  IgD+  IgM+  CD43−  CD21+  CD24+ (MZ-like B 
cell) for wt and Eµ-PKCβIItg mice as defined by the strategy illustrated in Supplementary Figure 2. Black dots in 
these graphs refer to wt and homozygous Eµ-PKCβIItg progeny derived from mating heterozygous Eµ-PKCβIItg 
mice. Red dots refer to wt mice with similar genetic backgrounds (C57BL/6) that are alike in terms of age to 
the transgenic mice. (D) upper panels H&E staining of splenic tissue from wt and Eµ-PKCβIItg mice. Lower 
panels anti-IgM staining of spleen sections from wt and Eµ-PKCβIItg mice. These images are representative 
of n = 2 experiments using splenic tissue from different mice that had been aged in excess of 12 months. Inset 
arrows indicate MZ. These histogram images have been published in the PhD thesis of AAA 43. (E) BCR-induced 
 Ca2+ flux in isolated splenic B cells from heterozygous and homozygous Eµ-PKCβIItg mice. Total flux was 
calculated as area under the curve is reported in arbitrary units. Statistical analysis for parts (A) (*P = 0.012), (B) 
(*P = 0.016), (C) (**P = 0.0052) and (E) (*P = 0.024) was performed using a Mann–Whitney U test.
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(Supplementary Figure 3). Taken together, these results suggest that B cell-targeted over expression of PKCβII 
results in accumulation of B-1a B cells in the peritoneum of Eµ-PKCβIItg mice.
Serum IgM levels are increased in Eµ-PKCβIItg mice. Consistent with the increased proportion of 
MZ and B-1a cells observed in spleen and peritoneum, Eµ-PKCβIItg mice also exhibited elevated levels of serum 
IgM compared to wt animals (Fig. 3D). As a negative control we analysed serum derived from a single  Rag1−/− 
mouse to show the background of detection for the assay used.
Peripheral blood from Eµ-PKCβIItg mice contains an expanded population of immature B 
cells. When  B220+ B cells derived from peripheral blood were analysed for IgD and IgM expression (Supple-
mentary Figure 4), an expansion of  IgDdim  IgM+/− B cells was evident in Eµ-PKCβIItg mice compared to wt mice 
as was a reduction of  IgD+  IgM+/− B cells (Fig. 4). Analysis of CD21 expression on  IgDdim  IgM+/− B cells and  IgD+ 
 IgM+/− B cells from Eµ-PKCβIItg and wt mice showed that the former were  CD21neg while the latter were  CD21+ 
(Supplementary Figure 4). As CD21 is a marker of B cell  maturity28, the lack of CD21 expression on  IgDdim 
 IgM+/− B cells from Eµ-PKCβIItg mice suggests that these cells are most likely immature B cells. Considering that 
the WBC and the B: B/T ratio in peripheral blood is not significantly different between Eµ-PKCβIItg and wt mice 
(Table 1), these results suggest that B cell-directed expression of PKCβII results in a shift towards expansion of 
the immature B cell population in peripheral blood.
Figure 3.  Effect of B cell-targeted expression of PKCβII on B cell populations in the peritoneum of 
Eµ-PKCβIItg and wt mice. Single cell suspensions prepared from peritoneal wash of Eµ-PKCβIItg and wt 
mice were stained with antibodies to B220, IgM, IgD, CD43, CD24, and CD5 and analyzed by flow cytometry. 
Quantitative comparisons were then made of the percentage  B220+ cells within the following gates (A)  IgD+ 
 IgMdim, (B)  IgDdim  IgM+, and (C)  IgDdim  IgM+  CD43+  CD24+ (B-1 cells) for wt and Eµ-PKCβIItg mice as defined 
by the strategy illustrated in Supplementary Figure 3. Black dots in these graphs refer to wt and homozygous 
Eµ-PKCβIItg progeny derived from mating heterozygous Eµ-PKCβIItg mice. Red dots refer to wt mice with 
similar genetic backgrounds (C57BL/6) that are alike in terms of age to the transgenic mice. (D) Comparison 
of IgM levels in serum derived from Rag2 deficient, wt, and heterozygous and homozygous Eµ-PKCβIItg 
mice. Statistical analysis for parts (A) (**P = 0.0040), (B) (*P = 0.042), and (C) (***P = 0.0010) was performed 
using a Mann–Whitney U test, for part (D) analysis was done using a one-way ANOVA and Tukey’s multiple 
comparisons test (P = 0.040).
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Discussion
Upregulated expression of PKCβII is frequently observed in the malignant cells of B lymphoproliferative 
 diseases29, and, in particular, CLL where its overexpression is a phenotypic  feature11. Because of this, we aimed 
to analyze the effect of PKCβII overexpression on the B cell compartment by generating a transgenic mouse strain 
where expression of PKCβII was driven by the Eµ promoter. Consistent with our initial hypothesis, the conse-
quence of B cell-directed PKCβII overexpression is a proportional change in FO, MZ-like, B-1 and immature 
B cell populations respectively in the spleen, peritoneum and peripheral blood of Eµ-PKCβIItg mice. Further 
examination of the Eµ-PKCβIItg mice shows suppression of BCR signaling in splenic B cells, and elevated levels 
of serum IgM. Although expansion of the B-1 cell compartment is a feature of several mouse models of  CLL15–19, 
we did not observe disease in Eµ-PKCβIItg mice and the proportion of B cells to combined B/T cells (taken as 
total lymphocytes) in these animals remained largely similar to that of wt mice despite aging them for 15 months. 
We conclude that PKCβII plays an important role in B cell development, with overexpression resulting in biased 
MZ-like and B-1 B cell development, but not in the pathogenesis of a CLL-like or other B lymphoproliferative 
disease in Eµ-PKCβIItg mice.
A limitation of this study is that our findings are based on data generated from analysis of animals that were 
derived from a single founder that was minimally backcrossed into the parental strain. The phenotype we describe 
could therefore potentially be a result of positional effect or an unidentified factor involved in producing the 
Eµ-PKCβIItg mice. However, comparison of B cell phenotypes within spleen, peritoneum and peripheral blood 
from the wt mice we analyzed are similar between littermate and non-littermate (i.e. C57BL/6 background) 
wt animals. These findings indicate that the genetic background of the strains used to generate Eµ-PKCβIItg 
mice had little, if any, effect on our observations. Furthermore, the phenomenon we observe is consistent with 
a mechanism whereby higher expression of PKCβII within B cells of Eµ-PKCβIItg mice could limit BCR signal-
ing by suppressing Btk activation. A well-described role of PKCβ in B cells is the phosphorylation of the  S180 
residue in Btk leading to downregulation of its  function4,5,30. Our own work shows that overexpressed PKCβII in 
primary CLL cells limits BCR signaling in the presence of  pS18011,31. The novel mouse model we describe herein 
recapitulates these findings and we show that BCR signaling in B cells from Eµ-PKCβIItg mice is suppressed. In 
contrast, a study describing the phenotype of PKCβ knockout mice showed enhanced BCR-mediated signaling 
in B cells from these  animals4, a phenomenon similar to that observed in a study of PKCβ inhibition on BCR 
 signaling32. This same study also showed that MZ and B1 B cell populations, as well as serum IgM levels were 
severely reduced in PKCβ knockout  mice4. Together, these observations provide support to our interpretation 
that suppressed BCR signaling resulting from targeted PKCβII overexpresson in Eµ-PKCβIItg mice leads to 
expansion of MZ-like and B1 B cells within total B cell populations and increased serum IgM levels. Further 
complementary support can be found in our observation that splenic B cell populations are slightly increased in 
Eµ-PKCβIItg mice, whilst Leitges et al.4 observed a slight decrease in these populations in their PKCβ knockout 
mice. Taken together, these observations suggest that the phenotype we observe is most likely due to transgenic 
overexpression of PKCβII rather than a confounding factor.
Figure 4.  Effect of B cell-targeted expression of PKCβII on B cell populations in peripheral blood of 
Eµ-PKCβIItg and wt mice. Single cell suspensions prepared from peripheral blood and bone marrow of 
Eµ-PKCβIItg and wild type mice were stained with antibodies to B220, IgM, IgD, and CD21 and analyzed 
by flow cytometry. Quantitative comparisons were then made of the percentage  B220+ cells within the 
following gates (A)  IgD+  IgM+/−, and (B)  IgDdim  IgM+/− for wt and Eµ-PKCβIItg mice as defined by the strategy 
illustrated in Supplementary Figure 4. Black dots in these graphs refer to wt and homozygous Eµ-PKCβIItg 
progeny derived from mating heterozygous Eµ-PKCβIItg mice. Red dots refer to wt mice with similar genetic 
backgrounds (C57BL/6) that are alike in terms of age to the transgenic mice. Statistical analysis for parts (A) 
(*P = 0.030) and (B) (*P = 0.023) was performed using a Mann–Whitney U test.
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In the current study we have focused on PKCβII and have not considered its splice variant PKCβI. Since we 
have not silenced the expression of the gene that codes for PKCβ in our system, we cannot rule out the contribu-
tion of PKCβI to the phenotype we have generated. Future studies crossing the Eµ-PKCβIItg mouse with a PKCβ 
null mouse would enable us to determine the role of PKCβII in B cells more precisely.
It is intriguing that despite the noted lineage biases observed in B cell populations in the Eµ-PKCβIItg mice, 
aged animals did not develop a disease endpoint. A possible reason for this could be that overexpression of 
PKCβII alone is not sufficient to drive the pathogenesis in B lymphoid diseases. However, Eµ-PKCβIItg mice 
may be more susceptible to the development of these diseases since it has been demonstrated that, for example, 
in colon cancer, overexpression of PKCβII promotes development of disease by increasing the sensitivity of 
colonic epithelial cells to carcinogenic  stimuli33,34. Indeed, this may be particularly relevant for CLL because this 
disease appears to develop from a lymphocytosis of B-1 cells in both mice and  humans14–17. If this hypothesis is 
correct, Eµ-PKCβIItg mice crossed with another mouse model of CLL, such as the Tcl-1 model, would exhibit 
accelerated development of disease because of the expanded population of B-1 cells. An alternative reason for 
the lack of disease development may be that the expression levels of PKCβII achieved in our mouse model are 
not high enough to facilitate neoplastic transformation. Our previous work in CLL showed that the malignant 
cells in this disease express up to sevenfold greater amounts of this PKC isozyme than do normal B  cells17. In 
the current study we were only able to achieve an approximate twofold increase of PKCβII in Eµ-PKCβIItg 
compared to wt mice.
We propose that the modest increase in protein levels of PKCβII observed in Eµ-PKCβIItg mice alters BCR 
signaling resulting in skewed representation of B cell population subsets in the periphery with expansion of 
MZ-like cells, B-1 B cells and immature B cells as we describe in this study. PKCβII in B cells has two key targets; 
CARMA1 (CARD11) which, when phosphorylated, combines with MALT1 and Bcl10 to form a complex that 
recruits TAK1 to stimulate activation of the NFκB and JNK signaling pathways and promote cell  survival35–37, 
and Btk where  S180 phosphorylation downregulates its function as discussed  above5. Hence, overexpression of 
PKCβII will preserve survival of B cells while limiting their ability to respond to BCR engagement. Such limita-
tion is likely to affect B cell differentiation and our observations can be explained by the "strength of signal" model 
suggested by Cariappa et al.38,39 where transitional B cells in the periphery respond to strong or "triggered" signals 
delivered via the BCR with commitment to FO B cell differentiation, while weaker or "tickled" BCR signals lead 
to differentiation towards MZ and B-1 B cells. The absence of BCR signals results in cell death due to neglect. 
This is likely the explanation for the phenotype of the MZ-like B cells we identify. These cells possess similarity to 
MZ precursor B  cells26, the presence of which are directly related to BCR signaling strength as is demonstrated in 
Aiolos- and CD22-deficient  mice27,38,40. Weakening of BCR signaling by overexpression of PKCβII is also likely 
to be responsible for the increased number of immature B cells in peripheral blood we observe in Eµ-PKCβIItg 
mice. Elimination of self-reactive B cell clones occurs at the pre-B cell stage within bone marrow, and is achieved 
either by receptor editing whereby B cell development is arrested while further gene rearrangements occur in 
order to mitigate self-reactivity41, or by the induction of apoptosis by strong BCR  signals42. Since both of these 
processes are driven by  Btk8, overexpression of PKCβII within pre-B cells of Eµ-PKCβIItg mice could limit 
strong self-antigen-driven BCR signaling by suppressing Btk activation thus generating the increased numbers 
of immature B cells seen here. We propose that the modestly increased levels of PKCβII in Eµ-PKCβIItg mice 
alters BCR signaling such that B cell subsets become skewed in the periphery as demonstrated; populations of 
MZ-like cells, B-1 B cells and immature B cells all  expand5,8,26,27,35–42.
In conclusion, we have generated a transgenic mouse strain with targeted overexpression of PKCβII within B 
lineage cells; Eµ-PKCβIItg. We show that the phenotype associated with Eµ-PKCβIItg mice skews development of 
MZ-like and immature B cells over FO B cells in the spleen and peripheral blood, and of B-1 B cells in the peri-
toneum, thereby providing in vivo data that support our hypothesis that overexpression of PKCβII might result 
in an expansion of B1 and MZ B cell populations. Considering the phenotype of the PKCβ knockout  mouse3, we 
have speculated that the increased populations of MZ-like and B-1a cells within the Eµ-PKCβIItg mouse would 
generate a phenotype where IgM antibodies would be prevalent and this was indeed the case. Thus, we have 
demonstrated that PKCβII specifically plays an important role in B cell development in mice. This novel mouse 
strain may be useful in studies of diseases involving BCR signaling, and, in particular, CLL.
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